#388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save lives

Episode Summary

Executive Summary: Peter Atiyah argues that modern prostate cancer screening should be more aggressive and nuanced than older guidelines allow. He says PSA testing, interpreted longitudinally and paired with MRI, PSA density/velocity, improved biopsy methods, and active surveillance, can catch lethal cancers earlier while reducing overtreatment. He also warns that finasteride can dangerously suppress PSA and mask cancer.

Main Topics: Why prostate cancer screening matters (Priority: 5/5): The episode frames prostate cancer as a major cause of male cancer death and argues early detection is highly valuable because prognosis is excellent when disease is found before metastasis. Problems with the old PSA screening paradigm (Priority: 5/5): Atiayah explains that early PSA use led to false positives, invasive transrectal biopsies, infections, and overtreatment of indolent disease, which fueled guideline pullbacks. Evidence that reducing screening worsened outcomes (Priority: 5/5): He argues stage IV diagnoses have risen after USPSTF guideline changes, suggesting less screening led to more late-stage, incurable prostate cancer detection. Modern screening tools: PSA trend, MRI, density, and velocity (Priority: 5/5): The episode emphasizes that PSA is more useful over time than as a single value, and that MRI plus PSA density/velocity can better identify clinically significant disease before biopsy. Safer, more accurate biopsy and active surveillance (Priority: 4/5): He highlights transperineal biopsy as safer than transrectal biopsy and describes active surveillance as a way to avoid overtreating low-risk cancers. The PLCO trial and flawed evidence base (Priority: 5/5): Atiayah says the major trial used to justify reduced screening was contaminated because the control group was frequently screened anyway, undermining the conclusion that PSA screening did not help. Finasteride as a hidden screening risk (Priority: 5/5): The episode warns that finasteride suppresses PSA and can hide warning signs unless clinicians correct the number and monitor trends carefully.

Key Arguments: PSA screening likely saves lives when used properly, and modern methods make it far better than the older PSA-to-biopsy pipeline. The main harm of early PSA screening was not the blood test itself but downstream false positives, infections from transrectal biopsy, and overtreatment of low-risk disease. Late-stage prostate cancer is increasing, especially stage IV disease, which suggests reduced screening has caused more cancers to be found too late for cure. PSA should be interpreted as a trajectory over time, not a one-time threshold, because individual PSA readings are noisy and vary naturally. MRI can now replace immediate biopsy in many cases by identifying suspicious lesions and helping calculate PSA density. Transperineal biopsy is safer and better targeted than transrectal biopsy, with far lower infection risk and better detection of high-grade disease. Active surveillance reduces overtreatment by monitoring low-risk cancers instead of treating every detected lesion immediately. The PLCO trial is a weak foundation for anti-screening guidelines because the control arm was heavily contaminated by outside PSA testing. Finasteride can halve PSA within a year and therefore requires correction; if ignored, it can delay diagnosis of metastatic cancer. Current guidelines should be revised because today’s screening tools and management pathways are much more precise than those available when anti-screening recommendations were made.

Data Points: Lifetime prostate cancer diagnosis risk: About 1 in 8 men - Speaker uses this to show how common prostate cancer is. Annual U.S. prostate cancer deaths: Roughly 36,000 - Used to argue the mortality burden remains substantial. Prostate cancer mortality ranking: Second leading cause of cancer death in men - Introduces why screening matters. Early-diagnosis survival: 15-year survival approaching 97% - Cited to emphasize excellent prognosis when caught early. Stage IV five-year survival: 38% - Used to show the severity of metastatic disease. Median survival after stage IV diagnosis: About 2.5 years / 30 months - Illustrates why late detection is dangerous. Mortality reduction in early screening trials: 44% and 64% - Two large trials are said to show routine PSA screening cut prostate cancer mortality. Metastatic disease prevented: Up to 3.1 cases per 1,000 screened men - Estimated benefit of screening in early trials. PSA fluctuation over time: Up to 15% day-to-day - Supports using longitudinal trends rather than a single reading. PSA increase after ejaculation: Up to 40% - Example of physiologic noise in PSA testing. Median PSA in healthy men in their 60s: 1.0 to 1.2 - Provides age-specific reference context. 95th percentile PSA in healthy men in their 60s: Up to 4.9 - Shows wide normal variation. Red-flag PSA velocity when baseline PSA <4: >0.35 ng/mL per year over 18 months - Threshold used in the practice described. Red-flag PSA velocity when baseline PSA >4: >0.75 ng/mL per year over 18 months - Threshold used in the practice described. PRIME trial biparametric MRI detection: 143/490 - Clinically significant cancers detected with contrast-free MRI. PRIME trial multiparametric MRI detection: 145/490 - Detection with contrast-enhanced MRI; essentially identical to biparametric MRI. Detection difference in PRIME trial: 0.4 percentage points - Statistically indistinguishable difference between MRI protocols. Transperineal biopsy infection rate in cited trial: 0 infections - Head-to-head trial of >1,700 patients. Transrectal biopsy infection rate: 5% to 7% - Widely reported complication rate compared with transperineal biopsy. U.S. urologists performing transperineal biopsy: About 37% - Shows adoption lag despite evidence. USPSTF guideline change: 2008: stop recommending screening for men over 70; 2012: against screening men of all ages - Historical policy shift criticized in the episode. PLCO control-arm contamination: 40% to 60% screened annually; over 90% had at least one PSA test by the final survey - Used to argue the trial compared screening vs. screening. Reanalyzed PLCO mortality reduction: 27% to 32% - Corrected analysis accounting for contamination. Finasteride PSA suppression: About one-third within 6 months; roughly half by 1 year - Explains why PSA must be adjusted in users. PSA correction on finasteride: At minimum double after 1 year; 2.3x after 2-7 years; 2.5x beyond 7 years - Practice-specific correction factors discussed. PSA trend on long-term finasteride: Average 2% annual decrease in cancer-free older men - Any rise becomes more concerning. Metastatic cancer rate in VA analysis: 6.7% vs 2.9% - Men on finasteride were diagnosed with metastatic cancer at more than double the rate of non-users.

Pivotal Quotes: "We stopped looking for early disease, so we started finding it late." — Peter Atiyah: Summarizes the argument that reduced screening increased late-stage diagnoses. "PSA is most value as a longitudinal trend, not a single snapshot." — Peter Atiyah: Core clinical message about how PSA should be interpreted today. "If you're on finasteride and your doctor doesn't understand the implications of that and how that impacts your PSA values, you could be sitting on a ticking time bomb without anybody knowing it." — Peter Atiyah: Warning about PSA suppression from finasteride masking cancer.

Implications: Listeners should discuss PSA screening early and regularly, especially if taking finasteride. Clinicians may need to modernize protocols with serial PSA, MRI, PSA density/velocity, transperineal biopsy, and active surveillance to reduce deaths and unnecessary treatment.